A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Trajenta tablet

Study type: Observational

Funder types: Industry

Identifiers

NCT01707147

1218.104

Details and patient eligibility

About

The aim of this study is to monitor safety and efficacy of treatment with linagliptin in Korean patients with type 2 diabetes mellitus in routine clinical settings.

Full description

Study Design:

Post Marketing study- Observational study

Enrollment: 3,219 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients who have been started on Trajenta in accordance with the approved label in Korea Patients who have signed on the data release consent form

Exclusion criteria

Patients with previous exposure to Trajenta and current participation in clinical trials

Trial design

3,219 participants in 1 patient group

Patients with Type 2 Diabetes Mellitus

Treatment:

Drug: Trajenta tablet